Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: ZYMERON CORPORATION
Awarding agency: Department of Defense / Defense Health Agency
Funding agency: Department of Defense / Defense Health Agency
Period of performance: 2023-09-15 to 2026-01-14
Current total value of award: $2999998.63
Description: DHA SMALL BUSINESS INNOVATION RESEARCH DIRECT TO PHASE II MEDICAL RESEARCH AND DEVELOPMENT CONTRACT FROM  PROPOSAL H2D-0119 TITLE  DEVELOPMENT FOR SHOCKDEFENDER AGAINST HEMORRHAGIC SHOCK